RxDoctor Payments Data

Renee Doll, MD

Pain Medicine · Yulee, FLNPI 1871823849

Payments from drug & device makers

$6,580in general payments, 2019–2025

Across 285 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Nevro Corp.$865
  • AbbVie$680
  • Boston Scientific$618
  • Amgen$428
  • Collegium Pharmaceutical, Inc.$396
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$6,552100%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,580 in reported general payments places this provider in the 70th percentile of 596 pain medicine providers in Florida.

See all pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$803,737
Medicare patients
937
Services billed
18,458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate30$58,504
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,667$46,137
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,247$42,252
Lidocaine232$38,583
Xtampza ErOxycodone Myristate58$25,102
BelbucaBuprenorphine Hcl31$23,582
QuliptaAtogepant17$20,244
LinzessLinaclotide17$16,817
ZtlidoLidocaine15$16,230
NucyntaTapentadol Hcl14$16,212
OxycontinOxycodone Hcl45$15,668
Nucynta ErTapentadol Hcl12$14,045
MovantikNaloxegol Oxalate28$13,739
Gabapentin848$11,613
Pregabalin476$11,495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta, Nucynta Er$396$78,941115 claims
PfizerNurtec Odt$278$58,50430 claims
AbbVieQulipta, Linzess$680$37,06134 claims
Scilex Pharmaceuticals Inc.Ztlido$388$16,23015 claims
Redhill Biopharma Inc.Movantik$22$13,73928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 596 pain medicine providers in Florida.

Other pain medicine in Yulee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →